Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015:2015:284168.
doi: 10.1155/2015/284168. Epub 2015 Dec 15.

Ruxolitinib Associated Tuberculosis Presenting as a Neck Lump

Affiliations

Ruxolitinib Associated Tuberculosis Presenting as a Neck Lump

Eamon Shamil et al. Case Rep Infect Dis. 2015.

Abstract

Tuberculosis is an opportunistic infection with protean clinical manifestations. We describe a case of Ruxolitinib induced miliary tuberculosis presenting as a neck lump. A 78-year-old female presented with a two-month history of right-sided neck lump associated with fever, night sweats, and significant weight loss. She had a past medical history that included myelofibrosis, being treated with Ruxolitinib. Examination demonstrated 4 × 4 cm right-sided cervical lymphadenopathy. A chest radiograph showed extensive shadowing in both lungs. CT scan demonstrated perilymphatic nodes in addition to the cervical mass. An ultrasound-guided biopsy of a cervical lymph node demonstrated confirmed Mycobacterium tuberculosis infection. It was hypothesized that use of Ruxolitinib through its selective inhibition of Janus-activated kinases 1 and 2 resulted in immunosuppression and miliary tuberculosis in this patient. The medication was stopped and a 12-month regime of antituberculosis therapy commenced. She remained well at one-year follow-up with resolution of lung involvement. Clinicians should consider tuberculosis as a differential diagnosis for patients presenting with a neck lump, particularly in those taking immunosuppressant medication such as Ruxolitinib. A multidisciplinary approach is needed to promptly treat the tuberculosis and consider discontinuation of Ruxolitinib.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Colomba C., Rubino R., Siracusa L., et al. Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. BMC Research Notes. 2012;5, article 552 doi: 10.1186/1756-0500-5-2101791285670497. - DOI - PMC - PubMed
    1. Baxter E. J., Scott L. M., Campbell P. J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. The Lancet. 2005;365(9464):1054–1061. doi: 10.1016/S0140-6736(05)71142-9. - DOI - PubMed
    1. Cervantes F., Vannucchi A. M., Kiladjian J.-J., et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047–4053. doi: 10.1182/blood-2013-02-485888. - DOI - PubMed
    1. Kralovics R., Passamonti F., Buser A. S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. The New England Journal of Medicine. 2005;352(17):1779–1790. doi: 10.1056/nejmoa051113. - DOI - PubMed
    1. Tefferi A. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. American Journal of Hematology. 2011;86(12):1017–1026. doi: 10.1002/ajh.22210. - DOI - PubMed

LinkOut - more resources